ReviewBlood cancer journal2020
Dissecting racial disparities in multiple myeloma.
Review in Blood cancer journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 4 syntheses or guidelines pooled it, 139 citations in OpenAlex.
- Epidemiology of Monoclonal Gammopathies in Sub-Saharan Africa: A Systematic Review and Meta-Analysis of MGUS and Multiple Myeloma.Tropical medicine & international health : TM & IH · 2026Pooled it
- Epidemiology, Treatment Trends, and Outcomes of Multiple Myeloma in the Middle East and Africa: A Systematic Review.Clinical hematology international · 2024Pooled it
- Disparities in Multiple Myeloma Treatment Patterns in the United States: A Systematic Review.Clinical lymphoma, myeloma & leukemia · 2023Pooled it
- Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies.JCO global oncology · 2022Pooled it
- FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Mass spectrometry-detected MGUS is associated with obesity and other novel modifiable risk factors in a high-risk population.Blood advances · 2024Trial
- MGUS in Black individuals in Soweto, South Africa screened by mass spectrometry: results of the PROMISE South Africa study.EClinicalMedicine · 2026Article
- Evolution of real-world frontline treatment patterns in multiple myeloma.Blood advances · 2026Article
- A Comparative Analysis of Multiple Myeloma Disease Burden in China and Globally From 1990 to 2023 and Future Trend Projections.Cancer medicine · 2026Article
- Human biomarker navigator.iMeta · 2026Review
- Quantifying the contribution of modifiable risk factors for progression of MGUS to multiple myeloma in a Veteran population.International journal of cancer · 2026Article
- Next-generation sequencing-based high-risk genomic stratification in multiple myeloma.Translational cancer research · 2026Article
- Temporal trends and demographic patterns in multiple myeloma incidence in the United States: a 24-year analysis of the CDC WONDER database (1999-2022).Blood cancer journal · 2026Observational
- The novel agent VP79s synergistically enhances venetoclax activity in multiple myeloma cells.Investigational new drugs · 2026Article
- A nested case-control study of monoclonal gammopathy of undetermined significance in the Multiethnic Cohort study.Blood advances · 2026Article
- Article
- Differential life expectancies and life years lost associated with multiple myeloma in the United States: a simulation modeling study.The oncologist · 2026Article
- Global epidemiology and burden of multiple myeloma from 1990 to 2021 with projections to 2045 based on the global burden of disease study 2021.Discover oncology · 2026Article
- Clinical practice pattern of management of plasma cell dyscrasia for kidney transplant candidates and recipients in the United States.Journal of onco-nephrology · 2026Article
- Association Between Monoclonal Gammopathy of Undetermined Significance and Cardiovascular Disease Risk: A Veterans Health Administration Study.Journal of the American Heart Association · 2026Observational
33 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Multiple myeloma (MM) is a fatal plasma cell dyscrasia with a median overall survival of 5 to 10 years. MM progresses from the more common but often subclinical precursor states of monoclonal gammopathy of undetermined significance (MGUS), and smoldering multiple myeloma (SMM) to overt MM. There are large racial disparities in all stages of the disease. Compared with Whites, Blacks have an increased MGUS and MM risk and higher mortality rate, and have not experienced the same survival gains over time. The roots of this disparity are likely multifactorial in nature. Comparisons of Black and White MGUS and MM patients suggest that differences in risk factors, biology, and clinical characteristics exist by race or ancestry, which may explain some of the observed disparity in MM. However, poor accrual of Black MGUS and MM patients in clinical and epidemiological studies has limited our understanding of this disparity and hindered its elimination. Disparities in MM survival also exist but appear to stem from inferior treatment utilization and access rather than underlying pathogenesis. Innovative and multidisciplinary approaches are urgently needed to enhance our understanding of disparities that exist at each stage of the MM disease continuum and facilitate their elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.